IHS Chemical Week

People & Business :: Companies

Schulman, Ferro prepare for next stage in bid, proxy fight

4:34 PM MDT | April 15, 2013 | —Vincent Valk and Rebecca Coons

Ferro sold its pharmaceuticals business, increased its earnings guidance, and issued a letter to shareholders, while A. Schulman fell short of estimates and amended CEO Joseph Gingo’s contract to extend it in the event of a “transformational acquisition” as the companies hunkered down for the next stage in Schulman’s $855-million hostile bid for Ferro. Gingo’s revised contract provides for a two-year extension, and Schulman specifically mentioned Ferro as the kind of deal that could trigger the extension....

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa